Evidence map›Paper›PMID 32574570›Full record

ArticleGastrointestinal endoscopy2020

Impact of COVID-19 on colorectal cancer disparities and the way forward.

Sophie Balzora, Rachel B Issaka, Adjoa Anyane-Yeboa, Darrell M Gray, Folasade P May

Open access · bronzeAbstract read
In one paragraph

Article in Gastrointestinal endoscopy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 91 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Sophie BalzoraDivision of Gastroenterology and Hepatology, NYU Langone Health, New York, New York, USA. Electronic address: Sophie.Balzora@nyulangone.org.
Rachel B IssakaClinical Research Division, Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Division of Gastroenterology, University of Washington School of Medicine, Seattle, Washington, USA.
Adjoa Anyane-YeboaCommonwealth Fund Fellowship in Minority Health Policy at Harvard University, Harvard Medical School, Boston, Massachusetts, USA.
Darrell M GrayDivision of Gastroenterology, Hepatology and Nutrition, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, USA.
Folasade P MayVatche and Tamar Manoukian Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, California, USA.
Harvard University · USNYU Langone Health · USThe Ohio State University · USUniversity of California, Los Angeles · USUniversity of Washington · US

Funding

Developing an intervention to improve follow-up of abnormal fecal immunochemical test results in a safety-net population using a mixed methods approachK08CA241296 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI ISSAKA, RACHEL B. · 2019 to 2023
$1.1M
NCI NIH HHS K08 CA241296NIMHD NIH HHS L32 MD012892
6 · The paper itself

Abstract

In response to the coronavirus disease 2019 (COVID-19) pandemic, the U.S. Surgeon General advised all hospitals and ambulatory care centers to delay nonurgent medical procedures and surgeries. This recommendation, echoed by a multigastroenterology society guideline, led to the suspension of colonoscopies for colorectal cancer (CRC) screening and surveillance. Although this temporary suspension was necessary to contain COVID-19 infections, we as gastroenterologists, patient advocates, and CRC researchers have witnessed the downstream impact of COVID-19 and this recommendation on CRC screening, research, and advocacy. These effects are particularly noticeable in medically underserved communities where CRC morbidity and mortality are highest. COVID-19-related pauses in medical care, as well as shifts in resource allocation and workforce deployment, threaten decades worth of work to improve CRC disparities in medically underserved populations. In this perspective, we present the unique challenges COVID-19 poses to health equity in CRC prevention and provide potential solutions as we navigate these uncharted waters.

Indexed as

BetacoronavirusCommunicable Disease ControlHealth Status DisparitiesColonoscopyColorectal NeoplasmsCoronavirus InfectionsCOVID-19HumansPandemicsPneumonia, ViralSARS-CoV-2United States

Identifiers

PMID32574570
PMCPMC7529970
OpenAlexW3035996746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.